Fidelity Advisor Series Vii · net assets $2.2B · 129 holdings as of July 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 96.1% · STIV: 2.3% · EP: 1.5% · DBT: 0.1%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $16.4M | $27.9M | $42.1M |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $28M | $27.8M | $28.9M |
| Net realized gain (non-derivative) | $56.2M | $107M | $30.4M |
| Net unrealized appreciation (non-derivative) | $-45M | $193M | $-46.8M |
The three months of the reporting period, as filed; month 3 ends July 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Abbvie Inc EC | $324M | 14.71% |
| Gilead Sciences Inc EC | $125M | 5.70% |
| Spyre Therapeutics Inc EC | $84.3M | 3.83% |
| Alnylam Pharmaceuticals Inc EC | $79.6M | 3.62% |
| Dianthus Therapeutics Inc EC | $78.1M | 3.55% |
| Cogent Biosciences Inc EC | $71.4M | 3.25% |
| Oruka Therapeutics Inc EC | $71.2M | 3.24% |
| Insmed Inc EC | $67.1M | 3.05% |
| Revolution Medicines Inc EC | $66M | 3.00% |
| Argenx Se EC | $65.9M | 3.00% |
| Ascendis Pharma A/s EC | $65.7M | 2.99% |
| Biogen Inc EC | $59.7M | 2.71% |
| Mbx Biosciences Inc EC | $53.9M | 2.45% |
| Amgen Inc EC | $52M | 2.37% |
| Amylyx Pharmaceuticals Inc EC | $49.4M | 2.25% |
| Vaxcyte Inc EC | $43.3M | 1.97% |
| Fidelity Revere Street Trust STIV | $43.2M | 1.96% |
| Moderna Inc EC | $35.1M | 1.60% |
| Relay Therapeutics Inc EC | $34.8M | 1.58% |
| Viridian Therapeutics Inc EC | $33.7M | 1.53% |
| Natera Inc EC | $31.4M | 1.43% |
| Kiniksa Pharmaceuticals International PLC EC | $31M | 1.41% |
| Vertex Pharmaceuticals Inc EC | $30.5M | 1.39% |
| Enliven Therapeutics Inc EC | $27.5M | 1.25% |
| Alumis Inc EC | $26.7M | 1.22% |
| Roivant Sciences Ltd EC | $26.3M | 1.20% |
| Structure Therapeutics Inc EC | $25.4M | 1.15% |
| Kymera Therapeutics Inc EC | $24M | 1.09% |
| Praxis Precision Medicines Inc. EC | $22.8M | 1.04% |
| Xenon Pharmaceuticals Inc EC | $21.4M | 0.98% |
| Celldex Therapeutics Inc EC | $19.5M | 0.89% |
| Parabilis Medicines Inc EC | $18M | 0.82% |
| Regeneron Pharmaceuticals Inc EC | $17.2M | 0.78% |
| Zenas Biopharma Inc EC | $15.5M | 0.70% |
| First Tracks Biotherapeutics Inc EC | $15M | 0.68% |
| Mirum Pharmaceuticals Inc EC | $14.3M | 0.65% |
| Viking Therapeutics Inc EC | $14.3M | 0.65% |
| Jade Biosciences Inc EC | $13.8M | 0.63% |
| Newamsterdam Pharma Company Nv EC | $12.4M | 0.57% |
| Dyne Therapeutics Inc EC | $12.1M | 0.55% |
| Climb Bio Inc EC | $11.9M | 0.54% |
| Arcus Biosciences Inc EC | $11.8M | 0.54% |
| Avalo Therapeutics Inc EC | $11.7M | 0.53% |
| Tyra Biosciences Inc EC | $11.3M | 0.51% |
| Cg Oncology Inc EC | $11.2M | 0.51% |
| Uniqure N.v. EC | $9.75M | 0.44% |
| Stoke Therapeutics Inc EC | $9.17M | 0.42% |
| Olema Pharmaceuticals Inc EC | $8.9M | 0.40% |
| Hemab Therapeutics Holdings Inc EC | $8.88M | 0.40% |
| Damora Therapeutics Inc EC | $8.64M | 0.39% |
| Fidelity Revere Street Trust STIV | $8.49M | 0.39% |
| Annexon Inc EC | $8.47M | 0.38% |
| Mineralys Therapeutics Inc EC | $8.45M | 0.38% |
| Ucb Sa EC | $8.38M | 0.38% |
| Cytomx Therapeutics Inc EC | $7.72M | 0.35% |
| Vor Biopharma Inc EC | $7.27M | 0.33% |
| Definium Therapeutics Inc EC | $7.02M | 0.32% |
| Tarsus Pharmaceuticals Inc EC | $6.49M | 0.30% |
| Disc Medicine Inc EC | $6.23M | 0.28% |
| Tenax Therapeutics Inc EC | $6.1M | 0.28% |
Showing top 60 of 129 holdings.
Loading...
